![](https://www.texasretina.com/wp-content/uploads/2024/07/Wang-ASRS-2024.png)
Robert C. Wang, MD, Presented Initial Study Results of New Non-infectious Uveitis Treatment at ASRS 2024 Annual Meeting
Texas Retina’s Robert C. Wang, MD, presented “Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase II Study (NEPTUNE)” at the 2024 Annual
read more![](https://www.texasretina.com/wp-content/uploads/2024/07/Abbey-ASRS-2024.png)
Ashkan M. Abbey, MD, Presented Real-world Outcomes of Fluocinolone Acetonide Intravitreal Implant for Non-infectious Uveitis at ASRS 2024 Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “36-month Optical Coherence Tomography Outcomes from CALM: A Registry Evaluating Treatment of Chronic Non-infectious Uveitis with the 0.18 mg Fluocinolone Acetonide Intravitreal Implant” at the
read more![](https://www.texasretina.com/wp-content/uploads/2024/07/Anand-and-Abbey-ASRS-Award.png)
Rajiv Anand, MD, and Ashkan Abbey, MD, Receive Senior Honor Awards from the American Society of Retina Specialists (ASRS)
In recognition of their time and contributions to the scientific programs of the organization’s annual meetings, Texas Retina’s Rajiv Anand, MD, and Ashkan M. Abbey, MD, recently earned the Senior Honor Award
read more![](https://www.texasretina.com/wp-content/uploads/2024/07/Sun_Safety_1_FB-copy.png)
July is UV Safety Month — Debunking Seven Common Myths About Sunglasses
When most people think of UV protection, they think of their skin and sunscreen. Did you know that long-term exposure to bright sunlight may also increase your risk of eye disease? July
read more![](https://www.texasretina.com/wp-content/uploads/2024/06/Screen-Shot-2024-06-24-at-1.33.50-PM.png)
June is Fireworks Eye Safety Awareness Month
Summer is here, and for many that means outdoor celebrations that include fireworks, especially around the 4th of July. Unfortunately, this also means an increase in eye injuries. Here are a few
read more![](https://www.texasretina.com/wp-content/uploads/2020/09/Texas-Retina_Timothy-Fuller-MD_742x593.jpg)
Texas Retina Associates Participating in Phase III Clinical Trial for Choroidal Melanoma
Under the leadership of principal investigator Timothy Fuller, MD, Texas Retina is now participating in the Phase III AU-011 clinical trial (CoMpass) for treatment of small choroidal (ocular) melanoma. Together with Aura
read more